Janssen Pharmaceutical Companies of Johnson & Johnson has reported new 96-week data from the Phase III AMBER clinical trial that evaluated the safety and efficacy of symtuza against a control for the treatment of antiretroviral treatment (ART) naïve adults with human immunodeficiency virus type 1 (HIV-1).

The control included two separate medications of darunavir / cobicistat and emtricitabine / tenofovir disoproxil fumarate.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The double-blind, active-controlled, non-inferiority international study randomly assigned 362 and 363 patients to receive symtuza and the control respectively.

New long-term results showed that 85% of ART-naïve adults with HIV-1 achieved virologic suppression at 96 weeks when treated with symtuza.

Only one patient treated with symtuza developed a nucleoside reverse transcriptase inhibitor resistance-associated mutation to emtricitabine (M184V), while a low virologic failure rate of 6% was also reported.

“The 96-week AMBER data further demonstrate the importance of symtuza as a treatment option for adults new to HIV therapy.”

Efficacy and safety outcomes were similar to the previous 48-week results in the symtuza group.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Among other data, the newly released results demonstrated consistency in bone, renal and lipid safety data with known profiles of tenofovir alafenamide and cobicistat.

University of North Carolina Centre for AIDS Research Clinical Core director and Janssen consultant Joseph Eron said: “The 96-week AMBER data further demonstrate the importance of symtuza as a treatment option for adults new to HIV therapy who may benefit from a single-tablet regimen that offers the protective barrier to resistance of darunavir along with the tolerability profile of TAF.

“Based on the US Department of Health and Human Services (DHHS) guidelines, darunavir-based regimens are a recommended option in situations where clinicians may not have all genotypic resistance test results, when patients may be at risk for sub-optimal adherence or in rapid initiation scenarios.”